Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
Kumano
K
K
Department of Urolegy, Kitasato University, School of Medicine, Sagamihara, Japan.
Irie
A
A
Mashimo
S
S
Endo
T
T
Koshiba
K
K
D000293:Adolescent; D000328:Adult; D002648:Child; D003404:Creatinine / Q000097:blood; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000628:therapy*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D003404:Creatinine; D008775:Methylprednisolone